Losartan

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H23ClN6O
Molecular Weight	422.911
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1=NC(Cl)=C(CO)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4

InChI

InChIKey=PSIFNNKUMBGKDQ-UHFFFAOYSA-N

InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)

HIDE SMILES / InChI

Molecular Formula	C22H23ClN6O
Molecular Weight	422.911
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/monograph/cozaar.html

Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) antagonist. Losartant is recommended as one of several preferred agents for the initial management of hypertension. Administration of losartan reduces the risk of stroke in patients with hypertension and left ventricular hypertrophy. Losartan is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin II receptor 9 Target ID: CHEMBL2094256 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16610806	Antagonist 2849		4.0 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 575 Sources: https://www.drugs.com/monograph/cozaar.html	Primary	Phase IV 63	COZAAR Approved Use Angiotensin II receptor antagonists are recommended as one of several preferred agents for the initial management of hypertension; other options include ACE inhibitors, calcium-channel blockers, and thiazide diuretics. While there may be individual differences with respect to specific outcomes, these antihypertensive drug classes all produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes. Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost). Launch Date 1995
Stroke 144 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s060lbl.pdf	Preventing	Phase IV 63	COZAAR Approved Use Preliminary evidence suggests that aspirin therapy at baseline in patients receiving losartan may reduce the risk of combined cardiovascular death, stroke, and acute MI compared with aspirin therapy at baseline in patients receiving atenolol, but there is evidence that this benefit does not apply to Black patients. Launch Date 1995
Diabetic nephropathy 37 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s060lbl.pdf	Primary	Approved 8583	COZAAR Approved Use Management of diabetic nephropathy manifested by elevated Scr and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes mellitus and hypertension. Launch Date 1995
Heart failure 106 Sources: https://www.drugs.com/monograph/cozaar.html	Primary	Approved 8583	COZAAR Approved Use Angiotensin II receptor antagonists are considered a reasonable alternative for inhibition of the renin-angiotensin system in patients with heart failure and reduced left ventricular ejection fraction (LVEF) who are intolerant of ACE inhibitors; because of their established benefits, ACE inhibitors are preferred. Launch Date 1995

C_max

Value	Dose	Co-administered	Analyte	Population
224 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LOSARTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
442 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LOSARTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LOSARTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.3% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LOSARTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 P-gp 1741 PEPT1 27 MRP4 290 OAT4 150 OAT1 725 OAT3 747	P-gp 2052 OATP2B1 122 UGT1A1 479 UGT1A3 470 UGT1A4 399 UGT1A5 56 UGT1A6 343 UGT1A7 249 UGT1A8 323 UGT1A9 423 UGT1A10 331 UGT2B4 278 UGT2B7 456 UGT2B10 131 UGT2B15 236 UGT2B17 237 UGT2B28 65

Drug as perpetrator

Target	Modality	Activity
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	moderate [IC50 138 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	no
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	slight
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	weak [IC50 210 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17674156/	yes [IC50 1.5 uM]
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17674156/	yes [IC50 1.6 uM]
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17674156/	yes [IC50 12 uM]
OAT4 150	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17674156/	yes [IC50 18 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	yes [IC50 524 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10877007/ Page: 137.0	yes [IC50 81 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/20222053/ Page: 6.0	yes [IC50 >100 uM]
PEPT1 29	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18824524/	yes [Ki 24 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	minor
UGT1A7 249	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	minor
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	minor
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	minor
UGT1A5 56	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	no
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	no
UGT2B10 131	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	no
UGT2B15 236	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	no
UGT2B28 65	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	no
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	no
OATP2B1 122	substrate 4014 Sources: https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.24.1_supplement.758.2	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1571937/	yes
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	yes
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	yes
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	yes
UGT2B17 237	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	yes
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18674515/	yes
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16029066/ Page: 2,8	yes	yes (co-administration study) Comment: coadministration with fluconazole (CYP2C9 inhibitor) increased AUC24 by 66%; coadministration with phenytoin (CYP2C9 inducer) increased AUC24 of drug by 17% and 29% in those with CYP2C91/1 genotype; Sources: https://pubmed.ncbi.nlm.nih.gov/16029066/ Page: 2,8
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16029066/ Page: 2.0	yes	yes (co-administration study) Comment: coadministration with ketoconazole or erythromycin (CYP3A4 inhibitors) had no effect on AUC24 of drug; coadministration with rifampin (CYP3A4 inducer) increased AUC24 of drug by 35%; Sources: https://pubmed.ncbi.nlm.nih.gov/16029066/ Page: 2.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/10715269/ Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6541	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6541
ChemicalBook	CB02485742	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02485742
ChemicalBook	CB32545285	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32545285
ChemicalBook	CB72485741	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72485741
ChemicalBook	CB8120081	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8120081
eMolecules	601417	https://www.emolecules.com/cgi-bin/more?vid=601417
MolPort	MolPort-003-666-553	https://www.molport.com/shop/molecule-link/MolPort-003-666-553
MolPort	MolPort-006-167-607	https://www.molport.com/shop/molecule-link/MolPort-006-167-607
ZINC	ZINC000003873160	http://zinc15.docking.org/substances/ZINC000003873160

PubMed

Title	Date	PubMed
The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure.	1999	10516413
Brain renin-angiotensin system and ouabain-induced sympathetic hyperactivity and hypertension in Wistar rats.	1999 Jul	10406832
Angioedema due to losartan.	1999 Sep	10492494
Losartan-induced angioedema.	1999 Sep	10492493
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion.	2000 Feb	10737671
[Cerebrovascular circulation during blockade of angiotensin receptors].	2000 Jan	10740833
Angiotensin II receptor blockade unmasks a depressor response to endothelin antagonists in rats.	2000 Mar-Apr	10796056
The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure.	2001 Apr	11247801
Angiotensin II stimulates cardiac L-type Ca(2+) current by a Ca(2+)- and protein kinase C-dependent mechanism.	2001 Apr	11247763
Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure.	2001 Feb	11216953
Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.	2001 Feb	11215846
Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats.	2001 Feb	11168946
Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II.	2001 Feb	11157878
Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats.	2001 Feb 16	11226399
Central interactions between angiotensin II and PGD(2) in the regulation of vasopressin and oxytocin secretion in dehydrated rats.	2001 Jan 19	11166690
Mannitol-induced toxicity in a diabetic patient receiving losartan.	2001 Mar	11247599
Effect of angiotensin II on venodilator response to nitroglycerin.	2001 Mar	11240977
MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia.	2001 Mar	11223426
Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis.	2001 Mar 6	11242510
Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells.	2001 Mar-Apr	11150859

Patents

Sample Use Guides

In Vivo Use Guide

For treatment of hypertension, Joint National Committee (JNC) 8 expert panel recommends initial dosage of 50 mg daily and target dosage of 100 mg daily (given in 1 dose or 2 divided doses) based on dosages used in randomized controlled studies.

Route of Administration: Oral

In Vitro Use Guide

From 30 to 40 min after confirmation of endothelium removal, the test compounds were incubated at a concentration of 0.1 uM. After an incubation period of 20 or 60 min, aortic preparations were treated with AII, using 3-fold increasing concentrations from 0.1 nM to 1 uM. Kb for binding with angiotensin receptor was 4 nM with 20 min incubation, and 9 nM with 60 min incubation.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:10 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:10 GMT 2025`
Record UNII	JMS50MPO89
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ALLISARTAN

Preferred Name

English

Losartan

Official Name

English

NSC-758699

Code

English

LOSARTAN [MI]

Common Name

English

LOZAP

Brand Name

English

1H-IMIDAZOLE-5-METHANOL, 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-

Systematic Name

English

ANGIZAAR

Brand Name

English

losartan [INN]

Common Name

English

2-BUTYL-4-CHLORO-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)IMIDAZOLE-5-METHANOL

Common Name

English

HGP1405

Code

English

HGP-1405

Code

English

DUP-89

Common Name

English

LOSARTIC

Brand Name

English

Losartan [WHO-DD]

Common Name

English

LOSARTAN [VANDF]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000000070